Increased serum levels of @entity8252 in XXXX with long- term disease.

@entity1 @entity627 @entity1252 @entity5145 @entity8252 @entity309
OBJECTIVE: To study the serum levels of @entity8252 in @entity1 with @entity309 ( @entity309 ), @entity1252 ( @entity1252 ), seronegative @entity5145 (SSd) and healthy donors. METHODS: The @entity8252 serum levels were measured by ELISA in sera from 50 @entity309 @entity1 , 30 @entity1 with @entity1252 , 30 @entity1 with SSd and 30 healthy donors. In @entity309 @entity1 , several clinical and demographic parameters were also obtained at the time of sample collection. @entity8252 levels were compared in different @entity309 subpopulations (positive or negative rheumatoid factor [RF], long term or recent onset disease, high or low disease activity). In addition, the possible association with other demographic and clinical parameters (gender, age, disease duration, etc) was also analysed. RESULTS: @entity309 @entity1 had significantly higher serum levels of @entity8252 (102.4 +/- 150 pg/ml; p = 0.0001) than @entity1252 @entity1 (9.8 +/- 15.3 pg/ml), SSd @entity1 (7.9 +/- 14.6 pg/ml) and healthy donors' (5.2 +/- 11.6 pg/ml). @entity309 @entity1 with a disease evolution less than 2 years showed lower @entity8252 levels (33.7 +/- 62.2 pg/ml) than those with long-term disease (152.4 +/- 64.6 pg/ml; p = 0.004). In addition, a significant correlation between @entity8252 in serum and the number of disease-modifying antirheumatic drugs (DMARDs) prescribed was detected in @entity309 @entity1 (r = 0.42; p = 0.002). No association between @entity8252 levels and age, gender, RF or disease activity was observed in this group. CONCLUSION: @entity8252 is elevated in @entity309 @entity1 , specially in those with long term disease, compared to other @entity627 . This finding supports that @entity8252 is involved in the perpetuation of @entity309 .
